Rachel Hurst

Dr. Rachel Hurst

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in EBioMedicine
Verified
Journal Article
Open access
HRHelen Ross-Adams
Helen Ross-Adams
ALA.D. Lamb
A.D. Lamb
MDM.J. Dunning
M.J. Dunning
SHS. Halim
S. Halim
JLJ. Lindberg
J. Lindberg
DND.E. Neal
D.E. Neal
Understanding the heterogeneous genotypes and phenotypes of prostate cancer is fundamental to improving the way we treat this disease. As yet, there are no validated descriptions of prostate cancer subgroups derived from integrated genomics linked with clinical outcome. In a study of 482 tumour, benign and germline samples from 259 men with primary prostate cancer, we used integrative analysis of copy number alterations (CNA) and array transcriptomics to identify genomic loci that affect expression levels of mRNA in an expression quantitative trait loci (eQTL) approach, to stratify patients into subgroups that we then associated with future clinical behaviour, and compared with either CNA or transcriptomics alone. We identified five separate patient subgroups with distinct genomic alterations and expression profiles based on 100 discriminating genes in our separate discovery and validation sets of 125 and 103 men. These subgroups were able to consistently predict biochemical relapse (p = 0.0017 and p = 0.016 respectively) and were further validated in a third cohort with long-term follow-up (p = 0.027). We show the relative contributions of gene expression and copy number data on phenotype, and demonstrate the improved power gained from integrative analyses. We confirm alterations in six genes previously associated with prostate cancer (MAP3K7, MELK, RCBTB2, ELAC2, TPD52, ZBTB4), and also identify 94 genes not previously linked to prostate cancer progression that would not have been detected using either transcript or copy number data alone. We confirm a number of previously published molecular changes associated with high risk disease, including MYC amplification, and NKX3-1, RB1 and PTEN deletions, as well as over-expression of PCA3 and AMACR, and loss of MSMB in tumour tissue. A subset of the 100 genes outperforms established clinical predictors of poor prognosis (PSA, Gleason score), as well as previously published gene signatures (p = 0.0001). We further show how our molecular profiles can be used for the early detection of aggressive cases in a clinical setting, and inform treatment decisions. For the first time in prostate cancer this study demonstrates the importance of integrated genomic analyses incorporating both benign and tumour tissue data in identifying molecular alterations leading to the generation of robust gene sets that are predictive of clinical outcome in independent patient cohorts.

1 April 2010 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
RHRachel Hurst
Rachel Hurst
CACharlotte N Armah
Charlotte N Armah
JDJack R Dainty
Jack R Dainty
DHDave J Hart
Dave J Hart
BTBirgit Teucher
Birgit Teucher
SFSusan J Fairweather-Tait
Susan J Fairweather-Tait
Background: Dietary recommendations for selenium differ between countries, mainly because of uncertainties over the definition of optimal selenium st

1 June 2011 in Food Chemistry
Verified
Journal Article
Closed access
DHD.J. Hart
D.J. Hart
SFS.J. Fairweather-Tait
S.J. Fairweather-Tait
MBMartin Broadley
Martin Broadley
SDS.J. Dickinson
S.J. Dickinson
IFI. Foot
I. Foot
RHRachel Hurst
Rachel Hurst

21 March 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AGAndrew J. Goldson
Andrew J. Goldson
SFSusan J. Fairweather-Tait
Susan J. Fairweather-Tait
CACharlotte N. Armah
Charlotte N. Armah
YBYongping Bao
Yongping Bao
MBMartin Broadley
Martin Broadley
RHRachel Hurst
Rachel Hurst
The uncertainty surrounding dietary requirements for selenium (Se) is partly due to limitations in biomarkers of Se status that are related to health outcomes. In this study we determined the effect of different doses and forms of Se on gene expression of selenoprotein S (SEPS1), selenoprotein W (SEPW1) and selenoprotein R (SEPR), and responses to an immune function challenge, influenza vaccine, were measured in order to identify functional markers of Se status. A 12 week human dietary intervention study was undertaken in 119 volunteers who received placebo, 50, 100 or 200 µg/day Se-enriched yeast (Se-yeast) or meals containing unenriched or Se-enriched onions (50 µg/day). Gene expression was quantified in RNA samples extracted from human peripheral blood mononuclear cells (PBMC's) using quantitative RT-PCR. There was a significant increase in SEPW1 mRNA in the Se-enriched onion group (50 µg/day) compared with the unenriched onion group. SEPR and SEPW1 did not change significantly over the duration of the supplementation period in the control or Se-yeast groups, except at week 10 when SEPW1 mRNA levels were significantly lower in the 200 µg/day Se-yeast group compared to the placebo group. Levels of SEPS1 mRNA increased significantly 7 days after the influenza vaccine challenge, the magnitude of the increase in SEPS1 gene expression was dose-dependent, with a significantly greater response with higher Se supplementation. This novel finding provides preliminary evidence for a role of SEPS1 in the immune response, and further supports the relationship between Se status and immune function. ClinicalTrials.gov [NCT00279812]

28 March 2024 in Journal of Medical Microbiology
Verified
Journal Article
Open access
RHRachel Hurst
Rachel Hurst
Daniel S BrewerDaniel S Brewer
Daniel S Brewer
AGAbraham Gihawi
Abraham Gihawi
JWJohn Wain
John Wain
CColin Cooper
Colin Cooper
There is growing evidence that altered microbiota abundance of a range of specific anaerobic bacteria are associated with cancer, including Peptoniphilus spp., Porphyromonas spp., Fusobacterium spp., Fenollaria spp., Prevotella spp., Sneathia spp., Veillonella spp. and Anaerococcus spp. linked to multiple cancer types. In this review we explore these pathogenic associations. The mechanisms by which bacteria are known or predicted to interact with human cells are reviewed and we present an overview of the interlinked mechanisms and hypotheses of how multiple intracellular anaerobic bacterial pathogens may act together to cause host cell and tissue microenvironment changes associated with carcinogenesis and cancer cell invasion. These include combined effects on changes in cell signalling, DNA damage, cellular metabolism and immune evasion. Strategies for early detection and eradication of anaerobic cancer-associated bacterial pathogens that may prevent cancer progression are proposed.

3 September 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
AGAbraham Gihawi
Abraham Gihawi
HWHenry M Wood
Henry M Wood
JCJeremy Clark
Jeremy Clark
JOJustin O’gRady
Justin O’gRady
RERosalind Eeles
Rosalind Eeles
Daniel S BrewerDaniel S Brewer
Daniel S Brewer
Oncomicrobes are estimated to cause 15% of cancers worldwide. When cancer whole-genome sequencing (WGS) data are collected, the microbes present are also sequenced, allowing the investigation of potential etiological and clinical associations. Interrogating the microbial community for 8908 patients encompassing 22 cancer types from the Genomics England WGS dataset revealed that only colorectal tumors exhibited unmistakably distinct microbial communities that can reliably be used to distinguish anatomical site [positive predictive value (PPV) = 0.95]. This pattern was validated in two independent datasets. Potential clinical relevance uncovered by our analyses included accurate detection of alphapapillomaviruses [human papillomavirus (HPV)] in oral cancers, when compared with current clinical standards, and the detection of rare, highly pathogenic viruses such as human T-lymphotropic virus–1. Biomarker investigations demonstrated statistically significant associations ( P < 0.05) between a subset of anaerobic bacteria and survival in certain subtypes of sarcoma. Our results contradict previous claims that each cancer type has a distinct microbiological signature but highlight the potential value of microbial analysis for certain cancers as WGS of tumor samples becomes common in the clinic.